Loading...

MDxHealth

DB:O6C
Snowflake Description

Reasonable growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
O6C
DB
€94M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
  • MDxHealth has significant price volatility in the past 3 months.
O6C Share Price and Events
7 Day Returns
2.1%
DB:O6C
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-58.8%
DB:O6C
-10.6%
DE Biotechs
-6.2%
DE Market
O6C Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MDxHealth (O6C) 2.1% -2.4% 25.6% -58.8% - -
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • O6C underperformed the Biotechs industry which returned -10.6% over the past year.
  • O6C underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
O6C
Industry
5yr Volatility vs Market

Value

 Is MDxHealth undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MDxHealth. This is due to cash flow or dividend data being unavailable. The share price is €1.554.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MDxHealth's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MDxHealth's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:O6C PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.54
ENXTBR:MDXH Share Price ** ENXTBR (2019-04-23) in EUR €1.57
ENXTBR:MDXH Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.121 $1.76
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MDxHealth.

DB:O6C PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ENXTBR:MDXH Share Price ÷ EPS (both in USD)

= 1.76 ÷ -0.54

-3.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MDxHealth is loss making, we can't compare its value to the Europe Biotechs industry average.
  • MDxHealth is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does MDxHealth's expected growth come at a high price?
Raw Data
DB:O6C PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.25x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
53%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MDxHealth, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MDxHealth's assets?
Raw Data
DB:O6C PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.81
ENXTBR:MDXH Share Price * ENXTBR (2019-04-23) in EUR €1.57
ENXTBR:MDXH Share Price converted to USD reporting currency Exchange rate (EUR/ USD) 1.121 $1.76
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:O6C PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ENXTBR:MDXH Share Price ÷ Book Value per Share (both in USD)

= 1.76 ÷ 0.81

2.16x

* Primary Listing of MDxHealth.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MDxHealth is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess MDxHealth's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. MDxHealth has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MDxHealth expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
53%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MDxHealth expected to grow at an attractive rate?
  • MDxHealth's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • MDxHealth's earnings growth is expected to exceed the Germany market average.
  • MDxHealth's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:O6C Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:O6C Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 53%
DB:O6C Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 20%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:O6C Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:O6C Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 84 12 8 1
2022-12-31 62 1 -2 1
2021-12-31 47 -6 -8 1
2020-12-31 37 -9 -14 4
2019-12-31 33 -14 -20 1
DB:O6C Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 28 -28 -32
2018-09-30 31 -28 -30
2018-06-30 33 -28 -28
2018-03-31 37 -19 -20
2017-12-31 41 -10 -12
2017-09-30 41 -8 -9
2017-06-30 41 -5 -5
2017-03-31 36 -11 -9
2016-12-31 30 -17 -13
2016-09-30 26 -17 -15
2016-06-30 23 -16 -17
2016-03-31 20 -15 -16

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • MDxHealth's earnings are expected to grow significantly at over 20% yearly.
  • MDxHealth's revenue is expected to grow by 20% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:O6C Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from MDxHealth Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:O6C Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.12 0.12 0.12 1.00
2022-12-31 -0.03 -0.03 -0.03 1.00
2021-12-31 -0.12 -0.12 -0.12 1.00
2020-12-31 -0.22 -0.22 -0.22 1.00
2019-12-31 -0.23 -0.23 -0.23 1.00
DB:O6C Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.54
2018-09-30 -0.53
2018-06-30 -0.53
2018-03-31 -0.39
2017-12-31 -0.25
2017-09-30 -0.18
2017-06-30 -0.10
2017-03-31 -0.19
2016-12-31 -0.29
2016-09-30 -0.34
2016-06-30 -0.40
2016-03-31 -0.37

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MDxHealth will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MDxHealth's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MDxHealth has a total score of 4/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MDxHealth performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MDxHealth's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MDxHealth does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare MDxHealth's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MDxHealth's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
MDxHealth's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MDxHealth Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:O6C Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 28.40 -32.45 44.80 4.28
2018-09-30 30.92 -30.19 44.86 4.43
2018-06-30 33.45 -27.94 44.92 4.57
2018-03-31 36.98 -20.11 42.03 4.04
2017-12-31 40.51 -12.29 39.14 3.51
2017-09-30 40.90 -8.65 36.44 2.63
2017-06-30 41.29 -5.02 33.74 1.75
2017-03-31 35.63 -9.10 32.34 1.86
2016-12-31 29.97 -13.17 30.95 1.98
2016-09-30 26.35 -14.89 29.36 2.54
2016-06-30 22.73 -16.61 27.77 3.11
2016-03-31 20.18 -15.54 25.06 3.18
2015-12-31 17.64 -14.47 22.36 3.26
2015-09-30 16.18 -13.59 20.62 2.76
2015-06-30 14.73 -12.70 18.87 2.26
2015-03-31 13.20 -13.98 18.60 2.32
2014-12-31 11.67 -15.26 18.32 2.38
2014-09-30 10.02 -15.82 16.92 2.53
2014-06-30 8.37 -16.38 15.52 2.69
2014-03-31 7.96 -16.28 14.37 3.63
2013-12-31 7.55 -16.18 13.22 4.57
2013-09-30 7.43 -15.04 12.46 5.70
2013-06-30 7.28 -13.84 11.63 6.79
2013-03-31 6.61 -12.73 10.64 6.81
2012-12-31 5.91 -11.53 9.59 6.79
2012-09-30 5.36 -11.26 9.31 6.70
2012-06-30 4.18 -9.37 7.90 5.50

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MDxHealth has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MDxHealth has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MDxHealth improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MDxHealth's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MDxHealth has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MDxHealth's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MDxHealth's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MDxHealth is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MDxHealth's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MDxHealth's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 91x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MDxHealth Company Filings, last reported 3 months ago.

DB:O6C Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 52.12 0.53 26.20
2018-09-30 52.12 0.53 26.20
2018-06-30 69.65 0.69 40.93
2018-03-31 69.65 0.69 40.93
2017-12-31 43.55 0.88 16.85
2017-09-30 43.55 0.88 16.85
2017-06-30 55.17 0.54 30.51
2017-03-31 55.17 0.54 30.51
2016-12-31 52.74 0.54 30.87
2016-09-30 52.74 0.54 30.87
2016-06-30 37.44 0.66 20.11
2016-03-31 37.44 0.66 20.11
2015-12-31 44.26 0.85 31.76
2015-09-30 44.26 0.85 31.76
2015-06-30 48.17 0.30 40.44
2015-03-31 48.17 0.30 40.44
2014-12-31 23.78 0.00 18.94
2014-09-30 23.78 0.00 18.94
2014-06-30 16.50 0.00 12.71
2014-03-31 16.50 0.00 12.71
2013-12-31 24.54 0.00 24.73
2013-09-30 24.54 0.00 24.73
2013-06-30 30.98 0.00 32.08
2013-03-31 30.54 0.00 31.62
2012-12-31 15.99 0.00 15.47
2012-09-30 15.99 0.00 15.47
2012-06-30 8.98 0.00 8.30
  • MDxHealth's level of debt (1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MDxHealth has less than a year of cash runway based on current free cash flow.
  • MDxHealth has less than a year of cash runway if free cash flow continues to grow at historical rates of 19.1% each year.
X
Financial health checks
We assess MDxHealth's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MDxHealth has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MDxHealth's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MDxHealth dividends. Estimated to be 0% next year.
If you bought €2,000 of MDxHealth shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MDxHealth's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MDxHealth's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:O6C Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:O6C Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MDxHealth has not reported any payouts.
  • Unable to verify if MDxHealth's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MDxHealth's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MDxHealth has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of MDxHealth's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess MDxHealth's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MDxHealth afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MDxHealth has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MDxHealth's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Mike McGarrity
AGE 55
TENURE AS CEO 0.2 years
CEO Bio

Mr. Michael K. McGarrity, also known as Mike, has been the Chief Executive Officer and Director at MDxHealth SA since February 19, 2019. Mr. McGarrity has more than 25 years of experience in the healthcare industry with a unique combination of device, diagnostics and biotechnology experience. Mr. Michael was the Chief Executive Officer and President of Nanosphere, Inc. since February 08, 2013. Mr. McGarrity served as the Chief Commercial Officer at Nanosphere, Inc., until February 8, 2013. He served as the Vice President of Sales & Marketing at Nanosphere, Inc. He served as the Chief Marketing Officer of Nanosphere, Inc., since October, 2005. Mr. McGarrity has more than 17 years of sales and marketing experience in the medical device industry. Prior to Nanosphere, he worked 13 years at Stryker Corporation. At Stryker, he served in leadership roles in marketing and strategic development, including as a Vice President of Marketing at Stryker Instruments, where he also worked Executive General management responsibility for a newly created business focused on interventional pain management. He has been a Director of Nanosphere, Inc., since February 2013. Michael was most recently the CEO of Sterilis Medical. He also had executive general management responsibility for a newly created business unit focused on interventional spine pain management. Michael received a Bachelor of Arts degree from the University of Notre Dame and began his career in commercial banking.

CEO Compensation
  • Insufficient data for Mike to compare compensation growth.
  • Insufficient data for Mike to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the MDxHealth management team in years:

1.7
Average Tenure
53
Average Age
  • The average tenure for the MDxHealth management team is less than 2 years, this suggests a new team.
Management Team

Mike McGarrity

TITLE
CEO & Director
AGE
55
TENURE
0.2 yrs

Kurt Schmidt

TITLE
Executive VP of Finance & Interim CFO
AGE
57

Wim Van Criekinge

TITLE
Chief Scientific Officer
AGE
46

Joe Sollee

TITLE
Chief Compliance Officer
AGE
53

Jean-Marc Roelandt

TITLE
CFO & Executive VP (Leave of Absence)
AGE
53
TENURE
2.3 yrs

Paul Marr

TITLE
Executive Vice President of Sales for North America
TENURE
1.7 yrs
Board of Directors Tenure

Average tenure and age of the MDxHealth board of directors in years:

2.5
Average Tenure
54.5
Average Age
  • The average tenure for the MDxHealth board of directors is less than 3 years, this suggests a new board.
Board of Directors

Koen Hoffman

TITLE
Chairman
AGE
50
TENURE
1.3 yrs

Mike McGarrity

TITLE
CEO & Director
AGE
55
TENURE
0.2 yrs

Ruth Devenyns

TITLE
Non-Executive Independent Director
COMPENSATION
$30K
AGE
54
TENURE
7.7 yrs

Wally Narajowski

TITLE
Independent Director
COMPENSATION
$30K
AGE
64
TENURE
3.5 yrs

Jan Groen

TITLE
Advisor to the Board
COMPENSATION
$487K
AGE
58
TENURE
0.2 yrs

James Herman

TITLE
Member of Scientific Advisory Board

Hilde Windels

TITLE
Director
COMPENSATION
$4K
AGE
53
TENURE
1.5 yrs

Gerrit Meijer

TITLE
Member of Scientific Advisory Board

Jonathan Epstein

TITLE
Member of Scientific Advisory Board
TENURE
8.1 yrs

Eric Wallen

TITLE
Member of Scientific Advisory Board
TENURE
8.1 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess MDxHealth's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MDxHealth has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

MDxHealth SA operates as a molecular diagnostics company in Germany, the Netherlands, Poland, the United States, rest of European Union, and internationally. The company develops and commercializes epigenetic and other molecular tests for cancer assessment and the personalized treatment of patients. Its tests are based on genetic, epigenetic (methylation) and other molecular technologies, and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The company’s product pipeline includes tests for prostate, bladder, kidney, cervical, and brain cancers. Its products include ConfirmMDx, a tissue-based epigenetic test for prostate cancer; SelectMDx, a urine-based mRNA test for prostate cancer; and AssureMDx bladder cancer detection test for patients with unresolved hematuria. The company’s preclinical development products comprise InformMDx, a tissue-based gene expression panel for prostate cancer; SelectMDx assay to a point of care testing platform; and MonitorMDx, a blood-based test for prostate cancer. It has collaboration agreement with 3D Signatures Inc. to evaluate prognostic test candidate for prostate cancer. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was founded in 2003 and is headquartered in Herstal, Belgium.

Details
Name: MDxHealth SA
O6C
Exchange: DB
Founded: 2003
€93,984,805
59,939,289
Website: http://www.mdxhealth.com
Address: MDxHealth SA
CAP Business Center,
Rue d’Abhooz, 31,
Herstal,
Liège, 4040,
Belgium
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ENXTBR MDXH Ordinary Shares Euronext Brussels BE EUR 27. Jun 2006
OTCPK MXDH.F Ordinary Shares Pink Sheets LLC US USD 27. Jun 2006
DB O6C Ordinary Shares Deutsche Boerse AG DE EUR 27. Jun 2006
LSE 0O8G Ordinary Shares London Stock Exchange GB EUR 27. Jun 2006
BATS-CHIXE MDXHB Ordinary Shares BATS 'Chi-X Europe' GB EUR 27. Jun 2006
Number of employees
Current staff
Staff numbers
232
MDxHealth employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 22:36
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/03/07
Last earnings filing: 2019/02/28
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.